Insights
Insights From Our Experts
Articles
Putting Data Science in the Spotlight
EVERSANA team shares key clinical insights at industry leading events Across the pharmaceutical and life sciences industries, the need for insightful data has never been more important. To truly understand how data can transform patient care, many companies turn to trusted experts. Real-world data becomes meaningful only when interpreted through a clinical, scientific and epidemiological lens. Our Data &…
“Nothing changes if nothing changes.”
Patients deserve quick and easy access to care. That’s why EVERSANA DIRECT goes beyond the “bare minimum” of DTP solutions, delivering a seamless end‑to‑end patient experience—from patient identification through prescription refills. Two-thirds of drug launches fall short of revenue goals, but a new approach is changing…
Navigating A New Era: Reflections on Canada’s Enhanced CDA-AMC Reimbursement Review Process
CDA-AMC’s recent enhancements to the reimbursement review process are reshaping the Canadian HTA landscape. With the first draft recommendations issued under the new framework in late 2025, clear themes are emerging that will influence how Sponsors…
Predicting PICO and Preparing for JCA: Insights from EVERSANA at ISPOR EU
As the EU HTA Regulation moves into implementation, Joint Clinical Assessment (JCA) is reshaping how evidence is planned and delivered across Europe. At ISPOR EU in Glasgow, EVERSANA’s Pamela Vo, VP, HEOR, joined a cross‑stakeholder panel featuring: …
The Combination Crossfire: Is Your Brand Strategy Strong Enough to Align Payers, Prescribers, and Patients?
Navigating Oncology’s Combination Era Combination therapy is now the norm in oncology, with most trials exploring multi-drug regimens. Success depends not just on clinical results, but on how well your brand stands out and performs within…
The Strategic Value of Medical & Scientific Fact-Checking in Medical, Legal and Regulatory Review
Posted by
Mary Mehrabian, PharmD, BCGP, BCMAS , Vaishnavi Gowda, MPhil, PhD , Michael DeLuca, PharmD, MBA, MSRA on January 14, 20261/14/26
In today’s highly regulated pharmaceutical industry, promotional and non-promotional materials must meet the highest standards of scientific accuracy, compliance, and trust. With growing scrutiny from regulators, healthcare professionals, and the public, fact-checking has become a strategic…
NAVLIN Daily 2025 Round-Up: The Pricing and Policy Trends Redefining Market Access
NAVLIN Daily by EVERSANA looks back at a year of rapid and often unpredictable global pricing and policy shifts that reshaped launch and access strategies worldwide. Throughout 2025, the NAVLIN Daily team supported the life sciences…
New Evidence Confirms Radiographic Progression-Free Survival (rPFS) as a Surrogate Endpoint for Overall Survival (OS) in Metastatic Castration-Resistant Prostate Cancer
Overall survival (OS) remains the gold standard in oncology trials, but waiting for long-term OS data can delay access to life‑prolonging therapies. Radiographic progression‑free survival (rPFS) has been increasingly used as a meaningful imaging-based primary endpoint…
No More Waiting: What the C-Suite Should Demand from an “AI Agency”
For C-suite leaders, the pressure to deliver speed, compliance and precision has never been greater, but most operating models are still built for a slower, manual era. Recent agency consolidations have exposed cracks in the system,…
A New Marketing Mandate in Community Oncology
As the next wave of oncology innovation—bispecific antibodies, ADCs, and CAR-T therapies—moves from academic centers into community practices, marketers face unprecedented clinical, operational, and financial hurdles. Success now demands a shift from traditional promotion to building…